skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Duloxetine in the management of diabetic peripheral neuropathic pain

Review

(1777) Views  (572) Full article downloads

Authors: Ormseth MJ, Scholz BA, Boomershine CS

Published Date July 2011 Volume 2011:5 Pages 343 - 356
DOI: http://dx.doi.org/10.2147/PPA.S16358

Michelle J Ormseth, Beth A Sholz, Chad S Boomershine
Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA

Abstract: Diabetic neuropathy affects up to 70% of diabetics, and diabetic peripheral neuropathic pain (DPNP) is the most common and debilitating of the diabetic neuropathies. DPNP significantly reduces quality of life and increases management costs in affected patients. Despite the impact of DPNP, management is poor with one-quarter of patients receiving no treatment and many treated with medications having little or no efficacy in managing DPNP. Duloxetine is one of two drugs approved by the United States Food and Drug Administration for DPNP management. Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) proven safe, effective, and cost-saving in reducing DPNP symptoms at a dose of 60 mg/day. Duloxetine doses greater than 60 mg/day for DPNP management are not recommended since they are no more efficacious and associated with more side effects; addition of pregabalin or gabapentin for these patients may be beneficial. Side effects of duloxetine are generally mild and typical for the SNRI class including nausea, dizziness, somnolence, fatigue, sweating, dry mouth, constipation, and diarrhea. Given its other indications, duloxetine is a particularly good choice for DPNP treatment in patients with coexisting depression, anxiety, fibromyalgia, or chronic musculoskeletal pain. Duloxetine treatment had no clinically significant effect on glycemic control and did not increase the risk of cardiovascular events in diabetes patients. However, duloxetine use should be avoided in patients with hepatic disease or severe renal impairment. Given its safety, efficacy, and tolerability, duloxetine is an excellent choice for DPNP treatment in many patients.

Keywords: duloxetine, diabetic peripheral neuropathic pain, review, treatment





 

Other articles by Dr Chad Boomershine



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
Preferences related to attention-deficit/hyperactivity disorder and its treatment
Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences
Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
Tapentadol extended-release for treatment of chronic pain: a review
Primary care for diabetes mellitus: perspective from older patients
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties